Meeting
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.
Authors
Rimas Vincas Lukas
Northwestern University, Chicago, IL
Rimas Vincas Lukas , E. Antonio Chiocca , Sylvia Christine Kurz , John Yu , Joseph C. Landolfi , Ganesh Rao , John A. Barrett , Jill Y. Buck , Nathan Demars , Amy Smith , John Miao , Qiang (John) Zhou , Arnold Bruce Gelb , Laurence Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03679754
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2053)
DOI
10.1200/JCO.2019.37.15_suppl.2053
Abstract #
2053
Poster Bd #
242
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone.
First Author: Rimas Vincas Lukas
Poster
2016 ASCO Annual Meeting
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
First Author: Francois M. Lebel
Poster
2023 ASCO Annual Meeting
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
First Author: Mason Webb
Poster
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca